论文部分内容阅读
纳入已经接受至少3个月门冬胰岛素30注射液治疗的2型糖尿病患者32例,联合口服格列美脲2周,采用动态血糖监测的方法,评估联合治疗前后血糖飘移、低血糖事件及日均胰岛素量的差异。结果联合格列美脲治疗后,血糖漂移及日均胰岛素量较前减少,差异有统计学意义(P<0.05),低血糖事件较前减少,但差异无统计学意义(P>0.05)。结论接受门冬胰岛素30注射液治疗的2型糖尿病患者,联合使用格列美脲可以降低血糖飘移,减少胰岛素用量,但降低低血糖风险作用显著。
32 patients with type 2 diabetes mellitus who had undergone atypical insulin aspart 30 injection for at least 3 months were enrolled in combination with oral glimepiride for 2 weeks. Dynamic glucose monitoring was used to assess the changes of blood glucose, hypoglycaemia and hypoglycaemia before and after the combination therapy Differences in the amount of insulin. Results After glimepiride treatment, the blood glucose level and the average daily insulin amount decreased compared with the previous period, the difference was statistically significant (P <0.05). The incidence of hypoglycemia was lower than before, but the difference was not statistically significant (P> 0.05). Conclusions Patients with type 2 diabetes mellitus treated with insulin aspart 30 injection can reduce glycemic drift and reduce insulin dosage, but reduce the risk of hypoglycemia.